SOLIGENIX, INC.: management transactions · United States · SEC (Form 4)

About SOLIGENIX, INC.

Soligenix, Inc. (ticker: SNGX) is a U.S.-based biopharmaceutical development company listed on the Nasdaq Capital Market in the United States. The company is headquartered in Princeton, New Jersey. Its corporate history reflects multiple prior name changes before adopting the Soligenix name in 2009, underscoring a long-running strategic evolution toward specialty development programs in underserved therapeutic areas. For investors, Soligenix should be viewed as a niche clinical-stage biotech rather than a commercial pharmaceutical company: value creation depends primarily on pipeline execution, clinical data, and access to non-dilutive or equity financing. Soligenix’s core business is centered on rare diseases and other indications with significant unmet medical need. Its most visible program is HyBryte™ (synthetic hypericin), a first-in-class photodynamic therapy being developed for cutaneous T-cell lymphoma (CTCL). This is the company’s lead asset and the main driver of investor attention. Soligenix also develops SGX302, which uses the same active ingredient for psoriasis, reflecting a dermatology platform built around synthetic hypericin. Beyond that, the pipeline includes SGX942, an innate defense regulator candidate for oral mucositis, and SGX945 for aphthous ulcers associated with Behçet’s disease. A second strategic pillar is the Public Health Solutions segment, which focuses on biodefense and infectious disease applications. This includes RiVax®, a ricin toxin vaccine candidate, vaccine programs targeting filoviruses such as Ebola and Marburg, and CiVax™, a COVID-19 vaccine candidate. This broader pipeline gives Soligenix optionality and reduces single-asset concentration, although it also stretches a company with limited financial resources across multiple development tracks. In competitive terms, Soligenix occupies a specialist position. It is not a market leader in size, revenue, or commercial penetration, but rather a science-driven micro-cap biotech competing through differentiated mechanisms, orphan-drug style development, and public-sector support. The company has disclosed historical support from U.S. agencies including NIAID, BARDA, and DTRA, which is meaningful because it can provide funding support and external validation for certain programs. Recent developments are highly material. In March 2026, Soligenix reported year-end 2025 financial results and highlighted important 2026 clinical milestones. In April 2026, the interim efficacy analysis of the pivotal Phase 3 FLASH2 trial for HyBryte™ in CTCL was completed, and the study was recommended to stop for futility. That is a negative clinical readout and materially increases pipeline risk. The company has also flagged liquidity pressure and the need to pursue additional capital, strategic transactions, and other financing sources. Overall, Soligenix remains a high-risk, event-driven Nasdaq biotech in the United States, with the investment case hinging on whether remaining programs can generate enough clinical and strategic value to offset the setback in HyBryte™.